Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Aug 11, 2021 1:59pm
198 Views
Post# 33685686

RE:Webinar for tmrrw

RE:Webinar for tmrrw
themagicbox wrote: Given that the old dumpster is back to his antics, lets bring some graded expectations to this:

-this webinar was already planned in advance and theyre unlikely to have the answer to the unexpected ALT elevation.

-the ALT elevation are in only in 3 people out fo the 35 people who are in the cohort i.e. 8%. And was not a serious adverse event i.e. unlike the hep guy from ph1, no one went to the hospital.

-given that its 8%, thats in line with general population having elevated ALTs as their base which is usually due to behavioral/lifestyle (we actually dont know how they screened the patients) or is "idiopathic".

-Lets assume its the drug and its due to the half life. Even if it is the drug/half life, in the past they've shown the half life to be related to efficacy so it may just be a case of requiring further dose titration. Which was already going to be the focus of both this AME and the first ph3 trial

The reality is they paused because of they hit a prespecified precautionary trigger and some people were still on dose for 1 more week, so by design they have to pause before letting those other people continue dose. 

Be careful with the FUD from duster, yukonjizza (my favorite clowns on this board) and the other dervative NPCs haha. They just want the cheap shares. Dumspter is porbably kicking himself in the a$$ for not accumulating enough below the $1 mark. Turd.


Amen Brother ... Someone who gets it.

Sure this is all strange but it's also very foreign terrain.

Though I am here for the drugs - don't get me wrong on that.
I also know we have the cash to carry us through the hurdles.
We have a capable team.
Most importantly, we have options - and - it's the full package that gets us where we need to go.

The old days of panic are gone because we have access to the resources we need.

Thankfully.

<< Previous
Bullboard Posts
Next >>